Abstracts Archive - Page 2279 of 2425 - ACR Meeting Abstracts

Abstract Number: 2150 • 2012 ACR/ARHP Annual Meeting
Action of Tofacitinib Via Human Dendritic Cells
Satoshi Kubo¹, Kunihiro Yamaoka², Shigeru Iwata¹ and Yoshiya Tanaka¹, ¹First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: Tofacitinib, an oral Janus Kinase (JAK) inhibitor, has gathered attention in treatment of Rheumatoid arthritis (RA). Although JAKs are well known for its importance…
Abstract Number: 2152 • 2012 ACR/ARHP Annual Meeting
Inhibition of Fucose Incorporation Abrogates the Development of Arthritis by Suppressing the Inflammatory Macrophage Development and TNF-α Production
Jun Li¹, Hui-Chen Hsu², PingAr Yang¹, Qi Wu¹, David M. Spalding³, W. Winn Chatham⁴, Robert P. Kimberly⁵, S. Louis Bridges Jr.⁶ and John D. Mountz⁷, ¹Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology and Rheum, University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Clinical Immun & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Clinical Immunology & Rheum, University of Alabama at Birmingham, Birmingham, AL, ⁷Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham and Birmingham VA Medical center, Birmingham, AL
Background/Purpose: Fucosylation, catalyzed by fucosyltransferases (Futs), is an important glycosylation process involved in inflammation, cell death, and differentiation. We have observed an extremely high positive correlation…
Abstract Number: 2153 • 2012 ACR/ARHP Annual Meeting
Target-Directed Development of a Proposed Biosimilar Rituximab (GP2013): Comparability of Antibody-Dependent Cellular Cytotoxicity Activity and Pre-Clinical Pharmacokinetics and Pharmacodynamics with Originator Rituximab
Antonio da Silva¹, Ulrich Kronthaler¹, Ines Meyer¹, Anastassia Papandrikopoulou², Thomas Stangler¹ and Jan Marinus Visser¹, ¹Preclinical Development, Sandoz Biopharmaceuticals / HEXAL AG, Holzkirchen, Germany, ²Medical Communications, Sandoz Biopharmaceuticals / HEXAL AG, Holzkirchen, Germany
Background/Purpose: Biosimilars are biologics approved by highly-regulated markets as similar to existing agents, with the aim of offering more affordable treatment and thereby increasing patient…
Abstract Number: 2154 • 2012 ACR/ARHP Annual Meeting
Regulation of Folate Pathway Related Genes in Methotrexate naïve and Methotrexate Treated Patients with Rheumatoid Arthritis
Marjolein Blits¹, Gerrit Jansen², Saskia Vosslamber¹, Yehuda G. Assaraf³ and Cornelis L. Verweij¹, ¹Pathology, VU University Medical Center, Amsterdam, Netherlands, ²Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ³Haifa, Israel
Background/Purpose: Rheumatoid arthritis (RA) is one of the most prevalent systemic autoimmune disorders. The folate antagonist methotrexate (MTX) is an anchor drug in the treatment…
Abstract Number: 2155 • 2012 ACR/ARHP Annual Meeting
The Annualized Progression of Radiologic Damage in Placebo Arms of Rheumatoid Arthritis Trials Is Much Lower Than the Mean Annual Progression Since Disease Onset
Jean-Marie Berthelot and Celine Cozic, Rheumatology Unit, Nantes University Hospital, Nantes, France
Background/Purpose : A previous meta-analysis by Graudal and Jürgens (Arthritis Rheum. 2010;62:2852–63) challenged the belief that biologics better protect rheumatoid arthritis (RA) from joint destruction…
Abstract Number: 2156 • 2012 ACR/ARHP Annual Meeting
Anti-Cyclic Citrullinated Protein Antibodies As a Predictor of Response to Tocilizumab in Patients with Rheumatoid arthritis A Prospective Study
Kensuke Kume¹, Kanzo Amano¹, Susumu Yamada¹, Kuniki Amano², Kazuhiko Hatta³, Hiroyuki Ohta⁴ and Noriko Kuwaba⁵, ¹Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ²Rheumatology, Sky Clinic, Hiroshima, Japan, ³Rheumatology, Hatta Clinic, Kure, Japan, ⁴Medical Research, hiroshima clinic, Hiroshima, Japan, ⁵Medical Research, Sanki Clinical Link, Hiroshima, Japan
Background/Purpose: Tocilizumab, interleukin-6 receptor antibody is very effective in patients with rheumatoid arthritis (RA). Anti-cyclic citrullinated protein antibodies (ACPA) are highly specific and sensitive for…
Abstract Number: 2157 • 2012 ACR/ARHP Annual Meeting
Resveratrol Counters Pro-Atherogenic Effects of Systemic Lupus Erythematosus and Rheumatoid Arthritis Plasma On Cholesterol Efflux in Human Macrophages
Allison B. Reiss¹, Iryna Voloshyna¹, Ofek Hai¹, Michael J. Littlefield¹, Elise Belilos², Kristina B. Belostocki², Lois A. Bonetti³, Gary C. Rosenblum² and Steven E. Carsons⁴, ¹Medicine, Winthrop University Hospital, Mineola, NY, ²Rheumatology, Winthrop University Hospital, Mineola, NY, ³Rheum & Immun, Winthrop University Hospital, Mineola, NY, ⁴Div of Rheumatology, Winthrop University Hospital, Mineola, NY
Background/Purpose: Our group has demonstrated that resveratrol, a plant polyphenol, possesses atheroprotective properties, enhancing expression of reverse cholesterol transport (RCT) proteins. We have reported that Systemic…
Abstract Number: 2158 • 2012 ACR/ARHP Annual Meeting
Baseline Folate Related Biomarkers in Serum and erythrocytes Are Not Associated with Methotrexate Response and Adverse Events in Rheumatoid Arthritis
Maurits C.F.J. De Rotte¹, Saskia M.F. Pluijm², Maja Bulatovic³, Johanna M.W. Hazes⁴ and Robert De Jonge¹, ¹Clinical Chemistry, Erasmus Medical Center, Rotterdam, Netherlands, ²Public Health, Erasmus Medical center, Rotterdam, Netherlands, ³Department of Paediatric Immunology, University Medical Centre Utrecht, Netherlands, ⁴Rheumatology, Erasmus MC, Rotterdam, Netherlands
Background/Purpose: Methotrexate (MTX) is the most commonly used drug in rheumatoid arthritis (RA). 30% of patients fail to respond to the drug or suffer from…
Abstract Number: 2159 • 2012 ACR/ARHP Annual Meeting
Correlation of a Multi-Biomarker Disease Activity Response Assessment to Disease Activity Score 28 (C-Reactive Protein) Response Assessment and Omeract Ramris Scores in a Placebo-Controlled Rheumatoid Arthritis Clinical Trial with Abatacept (ASSET)
DJ Haney¹, G. Cavet², P. Durez³, R. Alten⁴, Gerd Burmester⁵, P. P. Tak⁶, Anca Catrina⁷, C. Gaillez⁸, M. Le Bars⁸, S. Connolly⁹ and R. Townsend⁹, ¹Crescendo Bioscience Inc., South San Francisco, CA, ²Crescendo Bioscience, Inc., South San Francisco, CA, ³Université Catholique de Louvain, Brussels, Belgium, ⁴Schlosspark-Klinik, University Medicine, Berlin, Germany, ⁵Charité-Universitätsmedizin, Berlin, Germany, ⁶Academic Medical Center/University of Amsterdam, Amsterdam, the Netherlands; GlaxoSmithKline, Stevenage, United Kingdom, ⁷Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁸Bristol-Myers Squibb, Rueil Malmaison, France, ⁹Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: A novel multi-biomarker disease activity (MBDA) score has been validated and is a tool for monitoring disease activity in RA.1 Here, we evaluate the…
Abstract Number: 2160 • 2012 ACR/ARHP Annual Meeting
Fcγ Receptor IIIb Polymorphism Is Associated with Injection Reaction to Adalimumab in Patients with Rheumatoid Arthritis
Masako Tsukamoto¹, Yosuke Hashimoto¹, Tatsuhiro Ohshige¹, Keiko Yoshimoto², Yuko Kaneko³, Hideto Kameda² and Tsutomu Takeuchi⁴, ¹Division of Rheumatology, Department of Internal medicine, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Dept of Internal Medicine, Keio Univ School of Medicine, Shinjuku-ku, Japan, ⁴Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Biological agents targeting a specific molecule provide an effective means for therapeutic management of rheumatoid arthritis (RA), but infusion/injection reaction is a major adverse…
Abstract Number: 2161 • 2012 ACR/ARHP Annual Meeting
Methotrexate Polyglutamate Concentrations in Erythrocytes Are a Potential Tool for Therapeutic Drug Monitoring of Methotrexate Response in Rheumatoid Arthritis
Maurits C.F.J. De Rotte¹, Ethan den Boer², Maja Bulatovic³, Saskia M.F. Pluijm⁴, Johanna M.W. Hazes⁵ and Robert De Jonge¹, ¹Clinical Chemistry, Erasmus Medical Center, Rotterdam, Netherlands, ²Clinical Chemistry, Erasmus University Hospital, Rotterdam, Netherlands, ³Department of Paediatric Immunology, University Medical Centre Utrecht, Netherlands, ⁴Public Health, Erasmus Medical center, Rotterdam, Netherlands, ⁵Rheumatology, Erasmus MC, Rotterdam, Netherlands
Background/Purpose: Methotrexate (MTX) is the most commonly used drug in rheumatoid arthritis (RA). 30% of patients fail to respond to the drug or suffer from…
Abstract Number: 2121 • 2012 ACR/ARHP Annual Meeting
A Multi-Biomarker Disease Activity (VECTRA™ DA Algorithm) Score Reflects Clinical Disease Activity and Structural Changes in Rheumatoid Arthritis Patients Treated with Tocilizumab
Yoshiya Tanaka¹, Kentaro Hanami², Hisashi Tasaka¹, Shunsuke Fukuyo¹, Douglas J. Haney³, Nadine Defranoux³, Rebecca Bolce³, Guy Cavet³, David Chernoff³, Kunihiro Yamaoka¹, Kazuyoshi Saito¹ and Shintaro Hirata¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²The First Department of Internal Medicinei, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³Crescendo Bioscience Inc., South San Francisco, CA
Background/Purpose: The multi-biomarker disease activity (MBDA) score assessed with 0.2 mL serum has been reported as a novel composite disease activity index for patients with…
Abstract Number: 2122 • 2012 ACR/ARHP Annual Meeting
Plasma chemerin as a Useful Marker for Disease Activity in Patients with Rheumatoid Arthritis
Sang Tae Choi¹, You-Jung HA², Eun-Jin Kang³, Kwang-Hoon Lee⁴ and Jung-Soo Song¹, ¹Rheumatology, Chung-Ang University College of Medicine, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Kwanding University College of Medicine, Myongji Hospital, Goyang, South Korea, ³Rheumatology, Busan Medical Center, Busan, South Korea, ⁴Dongguk University Ilsan Hospital, Goyang, South Korea
Background/Purpose: Chemerin is an adipokine that is linked to adipogenesis and chemotaxis of the innate immune system. It is expressed on macrophage, dendritic cells, and…
Abstract Number: 2123 • 2012 ACR/ARHP Annual Meeting
Circulating Mir-223 Is Associated with Disease Activity and May Predict the Response to Therapy in Treatment naïve Patients with Early Rheumatoid Arthritis
Maria Filkova¹, Caroline Ospelt¹, Serena Vettori², Ladislav ŠEnolt³, Herman F. Mann⁴, Beat A. Michel⁵, Jiri Vencovsky⁶, Karel Pavelka³, Renate E. Gay¹, Steffen Gay¹ and Astrid Jüngel², ¹Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Switzerland, Zurich, Switzerland, ²Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, ³Institute of Rheumatology, Department of Clinical and Experimental Rheumatology of the 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ⁵Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁶Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Institute of Rheumatology, Prague, Czech Republic
Background/Purpose: Parameters/ predictors of treatment response in patients with early rheumatoid arthritis (ERA) are needed to optimize treatment management based on the expected disease course.…
Abstract Number: 2124 • 2012 ACR/ARHP Annual Meeting
Serum Concentrations of Soluble Interferon Receptor in Patients with Rheumatoid Arthritis
Masao Sato¹, Masao Takemura², Ryuki Shinohe³, Tsuneo Watanabe² and Katsuji Shimizu³, ¹Rheumatology, Matsunami General Hospital, Gifu, Japan, ²Informative Clinical Medicine, Gifu University, Gifu, Japan, ³Orthopaedic Surgery, Gifu University, Gifu, Japan
Background/Purpose: Interferon (IFN) exerts antiviral and antineoplastic activities, and is involved in immunoregulatory activities. IFN probably plays an important role in the pathogenesis of rheumatoid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].